Lilly's diabetes drug peglispro outperforms Lantus in 3 trials

05/13/2014 | Reuters

Data from several Phase III trials showed that Eli Lilly and Co.'s basal insulin peglispro was more effective than Sanofi's Lantus in lowering blood glucose levels among patients with type 2 diabetes, the company said. Lilly plans to submit the drug for regulatory review in the U.S. and Europe early next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health